Delap Wealth Advisory’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$398K Buy
1,566
+1
+0.1% +$233 0.13% 63
2026
Q1
$382K Sell
1,565
-260
-14% -$60.6K 0.14% 64
2025
Q4
$378K Buy
1,825
+416
+30% +$82.3K 0.15% 71
2025
Q3
$262K Buy
+1,409
New +$241K 0.11% 76
2025
Q2
Sell
-8,660
Closed -$1.44M 83
2025
Q1
$1.44M Buy
8,660
+7,040
+435% +$1.1M 0.8% 26
2024
Q4
$234K Sell
1,620
-79
-5% -$12.2K 0.14% 70
2024
Q3
$275K Sell
1,699
-336
-17% -$53.5K 0.17% 50
2024
Q2
$297K Sell
2,035
-4,787
-70% -$712K 0.14% 77
2024
Q1
$1.08M Buy
6,822
+180
+3% +$28.7K 0.44% 40
2023
Q4
$1.04M Buy
6,642
+5,159
+348% +$791K 0.47% 31
2023
Q3
$231K Buy
+1,483
New +$245K 0.22% 46
2023
Q2
Sell
-1,467
Closed -$227K 56
2023
Q1
$227K Sell
1,467
-1,098
-43% -$177K 0.23% 48
2022
Q4
$453K Buy
+2,565
New +$443K 0.47% 35

Other funds holding JNJ

Delap Wealth Advisory's JNJ Position: Q2 2026 in Review

Delap Wealth Advisory increased its Johnson & Johnson (JNJ) stake by 0.06% in Q2 2026, buying an estimated $233 and bringing the position to 1,566 shares worth $398K. The position accounts for 0.13% of the portfolio, ranked #63.

Delap Wealth Advisory first reported a position in JNJ in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.44M in Q1 2025. 4,688 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Delap Wealth Advisory held 1,566 shares of Johnson & Johnson worth $398K as of Q2 2026.
  • Delap Wealth Advisory bought 1 Johnson & Johnson share in Q2 2026, an estimated $233.
  • Johnson & Johnson made up 0.13% of Delap Wealth Advisory's portfolio in Q2 2026, its #63 holding.
  • Delap Wealth Advisory first reported a position in Johnson & Johnson in Q4 2022 and has held it in 13 quarters since.
  • Delap Wealth Advisory's Johnson & Johnson position peaked at $1.44M in Q1 2025.
  • 4,688 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Delap Wealth Advisory's 13F filing for Q2 2026, filed 4 Aug 2026.